About Calidi Biotherapeutics

We are committed to being at the forefront of cutting-edge research and innovation in the realm of oncology and arming the immune system to kill cancer.

At Calidi Biotherapeutics, we're advancing a series of ready-to-use product candidates. These are grounded in our cutting-edge platform that harnesses allogeneic stem cell technologies combined with viruses engineered to attack cancer, namely the vaccinia virus and adenovirus.

Two women in white lab coats in a laboratory.Two women in white lab coats in a laboratory.

Calidi throughout the years

2023

Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.

2022

Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.

2021

Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.

2020

Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.

2019

Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.

2018

Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.

2017

Lorem ipsum dolor sit amet consectetur. Lectus duis adipiscing rhoncus vitae. Augue enim ullamcorper iaculis tristique amet quam. Aliquam amet in sed ut. Bibendum egestas id morbi pretium mauris.

Calidi through the years

The company was founded in 2014, and is based in San Diego, California. Calidi's first patents were filed in 2015, and later awarded to Calidi for coverage in the United States and in key international territories. The patents encompass several patent families foundational to our SuperNova technology, used alone, and in combination with modern immunotherapies such as checkpoint inhibitors.

In 2016, Calidi acquired our wholly-owned subsidiary, based in Bernried, Germany, which is a pillar in the company's Research & Development and Process Development activities. In 2021 Calidi exclusively licensed the NeuroNova technology from Northwestern University and the City of Hope. This technology was developed over 15 years, and has shown strong indications of efficacy in published clinical trial results.

A tall building with a sign on the side of it.
ExecutivesMedical + ScientificBoard Members

Executive Team

Allan Camaisa

Allan Camaisa

Chief Executive Officer, Chairman of the Board of Directors
Boris Minev, MD

Boris Minev, MD

President, Medical and Scientific Affairs
Andrew Jackson

Andrew Jackson

Chief Financial Officer
Stephen Thesing

Stephen Thesing

Chief Business Officer
Wendy Pizarro, Esq.

Wendy Pizarro, Esq.

Chief Administrative Officer and Chief Legal Officer
Antonio F. Santidrian, PharmD, PH.D.

Antonio F. Santidrian, PharmD, PH.D.

Chief Scientific Officer
Amish Patel, PH.D.

Amish Patel, PH.D.

Senior Vice President of Technical Operations
David Sans Ph.D., MBA

David Sans Ph.D., MBA

Chief Corporate Development
 Barbara Haertl, PH.D.

Barbara Haertl, PH.D.

Associate Vice President, Manufacturing Operations
Thomas Herrmann, PH.D.

Thomas Herrmann, PH.D.

Associate Vice President, R&D, Process & Assay Development

Medical & Scientific Advisors

Karen Aboody, MD

Karen Aboody, MD

Ewa Carrier, MD

Ewa Carrier, MD

Santosh Kesari, MD/PH.D.

Santosh Kesari, MD/PH.D.

Matt S. Lesniak, MD

Matt S. Lesniak, MD

Ashok Srivastava, MD/PH.D.

Ashok Srivastava, MD/PH.D.

W.K. Alfred Yung, MD

W.K. Alfred Yung, MD

Dmitriy Zamarin, MD/PH.D.

Dmitriy Zamarin, MD/PH.D.

Our pipeline is robust and ever-evolving, driven by our commitment to pioneering breakthroughs in cancer treatment.

Explore Pipeline

Board of Directors

Allan Camaisa

Allan Camaisa

James A. Schoeneck

James A. Schoeneck

David LaPré

David LaPré

George Ng

George Ng

Scott Leftwich

Scott Leftwich

Alan Stewart

Alan Stewart